Research scientists working at the Imperial Cancer Research Fund in London have this week disclosed the development of a drug that has the quality of arresting cancer growth.
Research scientists working at the Imperial Cancer Research Fund in London have this week disclosed the development of a drug that has the quality of arresting cancer growth. The drug -- codenamed ICRF 159-was first synthesised in the ICRF laboratories four years ago, and has since been used in animal and human trials.
The scientists who have been working on the development of the drug describe it as significant. ICRF 159 has been shown to prevent the development of secondary cancer growths, one of the characteristics of the disease that makes cure difficult. The researchers have emphasised that tests to date have been concentrated on preventing secondary tumours. It will take some time to complete the animal and human clinical tests and evaluate the results.
The Imperial Cancer Research Fund is one of the major cancer research centres of the world, and in the past few years has made a number of major contributions in expanding international understanding of the possible causes of cancer, and possible counter-agents.
Two scientists at the ICRF headquarters in London gave details of the development and operation of ICRF 159.: